Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Fusobacterium nucleatum promotes colorectal cancer through neogenesis of tumor stem cells
Qinying Wang, … , Yongzhi Yang, Yanlei Ma
Qinying Wang, … , Yongzhi Yang, Yanlei Ma
Published December 10, 2024
Citation Information: J Clin Invest. 2025;135(3):e181595. https://doi.org/10.1172/JCI181595.
View: Text | PDF
Research Article Gastroenterology Oncology

Fusobacterium nucleatum promotes colorectal cancer through neogenesis of tumor stem cells

  • Text
  • PDF
Abstract

Intestinal stem cells are crucial for maintaining intestinal homeostasis, yet their transformation into tumor stem cells in the context of microbial infection remains poorly understood. Fusobacterium nucleatum is frequently associated with the onset and progression of colorectal cancer (CRC). In this study, we uncovered that F. nucleatum colonized the depths of gut crypts in both patients with CRC and mouse models. Through single-cell sequencing analysis, we demonstrated that F. nucleatum infection reprogrammed crypt cells and activated lymphocyte antigen 6 complex, locus A+ ( LY6A+, also known as stem cell antigen 1 [Sca-1]) revival stem cells (RSCs), promoting their hyperproliferation and subsequent transformation into tumor stem cells, which accelerated intestinal carcinogenesis. Mechanistically, we identified LY6A as a glycosylphosphatidylinositol-anchored (GPI-anchored) membrane receptor for F. nucleatum. Upon binding, F. nucleatum induced the upregulation of ribosomal protein S14 (RPS14) via the LY6A receptor, driving RSC hyperactivity and tumorigenic conversion. Functional studies showed that genetic ablation of Ly6a in intestinal epithelial cells or Rps14 in LY6A+ RSCs substantially reduced F. nucleatum colonization and tumorigenesis. Moreover, analysis of clinical CRC cohorts revealed a strong correlation between F. nucleatum infection, RSC expansion, and elevated RPS14 expression in tumor tissues. These findings highlight an alternative F. nucleatum/LY6A/RPS14 signaling axis as a critical driver of CRC progression and propose potential therapeutic targets for effective CRC intervention.

Authors

Qinying Wang, Tingting Hu, Qinyuan Zhang, Yichi Zhang, Xiaoxu Dong, Yutao Jin, Jinming Li, Yangyang Guo, Fanying Guo, Ziying Chen, Peijie Zhong, Yongzhi Yang, Yanlei Ma

×

Figure 3

LY6A-specific interaction with F. nucleatum surface membrane proteins.

Options: View larger image (or click on image) Download as PowerPoint
LY6A-specific interaction with F. nucleatum surface membrane proteins.
(...
(A) FISH assay detecting F. nucleatum in direct contact with LY6A-tdTomato+ cells in mouse colon. (B) Representative Western blots of LY6A expression in tumor tissues from PBS- and F. nucleatum–treated mice. (C) Exogenous LY6A expression in HEK293 cells detected by immunoblotting. (D) Exogenous LY6A expression in HEK293 cells increased F. nucleatum attachment, as shown by adhesion assay. (E) Knockdown of LY6A in CT26 cells detected by immunoblotting. shNC, negative control shRNA. (F) Knockdown of LY6A reduced F. nucleatum attachment in CT26 cells, as shown by adhesion assay. (G) Schematic diagram showing F. nucleatum–specific surface membrane proteins interacting with LY6A, identified by IP–mass spectrometry. (H) Exogenous Flag-LY6A expression detected by immunoblotting. (I) Screening of F. nucleatum adhesins by IP assay and silver staining. (J) Strategy for specific Ly6a conditional KO in the gut. (K) Representative images of tumor burden in the colon and rectum of PBS- and F. nucleatum–treated Vil1CreERT2 Ly6afl/fl mice. (L) Tumor numbers and loads in the colon and rectum, measured at the end of the study. (M) F. nucleatum distribution within tumors of WT, Vil1CreERT2 Ly6afl/fl, and Ly6a-DTA mice. Scale bars: 100 μm (A and M). Representative data are presented as the mean ± SEM of at least 3 assays. *P < .05, **P < .01, and ***P < .001, by 2-tailed Student’s t test (D and F) and 2-way ANOVA with post hoc Tukey’s multiple-comparison test (L).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts